Table 1.

Oncology drugs associated with stress cardiomyopathy

Oncology drug(s)	References
5-Fluorouracil	Cheriparambil KM, et al. Angiology. 2000 [23] Dalzell JR, et al. Anticancer Drugs. 2009 [24] Gianni M, et al. Blood Coagul Fibrinolysis. 2009 [35] Kobayashi N, et al. J Nippon Med Sch. 2009 [21] Stewart T, et al. Intern Med J. 2010 [22] Basselin C, et al. Pharmacotherapy. 2011 [25] Radhakrishnan V, et al. J Pediatr Hematol Oncol. 2011 [19] Grunwald MR, et al. J Clin Oncol. 2012 [26] Ozturk MA, et al. Blood Coagul Fibrinolysis. 2013 [17] Knott K, et al. Int J Cardiol. 2014 [20]
Capecitabine	Qasem, et al. Am J Ther. 2014 [27] Y-Hassan S, et al. Cardiovasc Revasc Med. 2013 [28]
Cytarabine	Madias JE. Oncol Res Treat. 2015 [40] Baumann S, et al. Oncol Res Treat. 2014 [37]
Cisplatin, docetaxel	Toyooka S, et al. Gen Thorac Cardiovasc Surg. 2012 [38]
Cytarabine, daunorubicin	Goel S, et al.World J Clin Cases. 2014 [33]
Paclitaxel, hydroxyurea, 5-Fluorouracil, concurrent radiation	Schweizer MT, et al. J Clin Oncol. 2011 [41]
Axitinib	Ovadia D, et al. J Clin Oncol. 2015 [30]
Sunitinib	Numico G, et al. J Clin Oncol. 2012 [39]
Bevacizumab	Franco TH, et al. Ther Clin Risk Manag 2008 [31]
Rituximab	Smith SA, et al. Heart Fail Clin. 2013 [15] Ng KH, et al. BMJ Case Rep. 2015 [32]
Trastuzumab	Burgy M, et al. Anticancer Res. 2014 [42] Khanji M, et al. Clin Oncol (R Coll Radiol) 2013 [43]
Cetuximab, irinotecan	Kim L, et al. J Invasive Cardiol. 2008 [29]
Combretastatin	Bhakta S, et al. Clin Cardiol. 2009 [18]